VEA
KLRS

Virtus ETF Advisers’s Kalaris Therapeutics KLRS Stock Holding History

Virtus ETF Advisers’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-656
Closed -$59.5K – 486
2023
Q1 		$59.5K Sell
656
-253
-28% -$32.2K 0.03% 422
2022
Q4 		$107K Buy
+909
New +$154K 0.06% 437
2022
Q2 		– Sell
-455
Closed -$71K – 482
2022
Q1 		$71K Sell
455
-27
-6% -$5.39K 0.03% 350
2021
Q4 		$143K Buy
482
+75
+18% +$34.8K 0.05% 359
2021
Q3 		$235K Sell
407
-21
-5% -$9.73K 0.1% 227
2021
Q2 		$195K Buy
428
+103
+32% +$53.2K 0.08% 360
2021
Q1 		$175K Buy
325
+6
+2% +$5.04K 0.07% 340
2020
Q4 		$282K Buy
+319
New +$245K 0.12% 244

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Virtus ETF Advisers's KLRS Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Kalaris Therapeutics (KLRS) in Q2 2023, closing a stake of 656 shares — an estimated $59.5K sold.

Virtus ETF Advisers first reported a position in KLRS in Q4 2020 and held it in 8 quarters. The position peaked at $282K in Q4 2020. 94 funds tracked by Wall St. Rank hold KLRS as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Kalaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 656 Kalaris Therapeutics shares in Q2 2023, an estimated $59.5K.
  • Virtus ETF Advisers first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 8 quarters.
  • Virtus ETF Advisers's Kalaris Therapeutics position peaked at $282K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.